Anson Funds Management LP increased its stake in SELLAS Life Sciences Group, Inc. (NASDAQ:SLS - Free Report) by 535.7% in the first quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 7,579,095 shares of the company's stock after purchasing an additional 6,386,829 shares during the quarter. SELLAS Life Sciences Group accounts for 1.3% of Anson Funds Management LP's investment portfolio, making the stock its 19th largest position. Anson Funds Management LP owned approximately 7.60% of SELLAS Life Sciences Group worth $8,185,000 as of its most recent filing with the Securities & Exchange Commission.
Other large investors have also made changes to their positions in the company. Brooklyn FI LLC purchased a new stake in shares of SELLAS Life Sciences Group in the 4th quarter worth about $677,000. Geode Capital Management LLC lifted its position in SELLAS Life Sciences Group by 21.2% during the fourth quarter. Geode Capital Management LLC now owns 733,546 shares of the company's stock worth $763,000 after buying an additional 128,355 shares during the period. Northern Trust Corp grew its position in SELLAS Life Sciences Group by 33.6% during the fourth quarter. Northern Trust Corp now owns 134,721 shares of the company's stock valued at $140,000 after acquiring an additional 33,878 shares during the period. Finally, Virtu Financial LLC grew its position in SELLAS Life Sciences Group by 30.9% during the first quarter. Virtu Financial LLC now owns 53,861 shares of the company's stock valued at $58,000 after acquiring an additional 12,706 shares during the period. Hedge funds and other institutional investors own 17.38% of the company's stock.
SELLAS Life Sciences Group Trading Up 0.3%
Shares of SELLAS Life Sciences Group stock traded up $0.01 on Friday, reaching $1.93. 666,031 shares of the company were exchanged, compared to its average volume of 2,528,440. The stock has a fifty day moving average price of $1.82 and a 200-day moving average price of $1.53. The firm has a market capitalization of $202.70 million, a price-to-earnings ratio of -6.02 and a beta of 2.26. SELLAS Life Sciences Group, Inc. has a fifty-two week low of $0.77 and a fifty-two week high of $2.27.
SELLAS Life Sciences Group (NASDAQ:SLS - Get Free Report) last issued its earnings results on Tuesday, August 12th. The company reported ($0.07) EPS for the quarter, topping the consensus estimate of ($0.08) by $0.01. On average, equities analysts anticipate that SELLAS Life Sciences Group, Inc. will post -0.57 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Separately, Maxim Group lifted their price objective on SELLAS Life Sciences Group from $4.00 to $7.00 and gave the stock a "buy" rating in a report on Wednesday, July 16th. One research analyst has rated the stock with a Buy rating, According to MarketBeat.com, the company has a consensus rating of "Buy" and a consensus price target of $7.00.
View Our Latest Report on SLS
About SELLAS Life Sciences Group
(
Free Report)
SELLAS Life Sciences Group, Inc, a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer.
Read More
Before you consider SELLAS Life Sciences Group, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and SELLAS Life Sciences Group wasn't on the list.
While SELLAS Life Sciences Group currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
